- Home
- STFS vs LPCN Comparison
STFS vs LPCN Comparison
Compare STFS & LPCN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- STFS
- LPCN
- Stock Information
- Founded
- STFS 2015
- LPCN 1997
- Country
- STFS China
- LPCN United States
- Employees
- STFS N/A
- LPCN N/A
- Industry
- STFS
- LPCN Biotechnology: Pharmaceutical Preparations
- Sector
- STFS
- LPCN Health Care
- Exchange
- STFS NYSE
- LPCN Nasdaq
- Market Cap
- STFS 16.2M
- LPCN 16.1M
- IPO Year
- STFS 2024
- LPCN N/A
- Fundamental
- Price
- STFS $1.03
- LPCN $3.29
- Analyst Decision
- STFS
- LPCN Strong Buy
- Analyst Count
- STFS 0
- LPCN 2
- Target Price
- STFS N/A
- LPCN $9.00
- AVG Volume (30 Days)
- STFS 370.9K
- LPCN 59.4K
- Earning Date
- STFS 02-14-2025
- LPCN 08-07-2025
- Dividend Yield
- STFS N/A
- LPCN N/A
- EPS Growth
- STFS N/A
- LPCN N/A
- EPS
- STFS 0.01
- LPCN N/A
- Revenue
- STFS $16,754,197.00
- LPCN $3,674,834.00
- Revenue This Year
- STFS N/A
- LPCN N/A
- Revenue Next Year
- STFS N/A
- LPCN N/A
- P/E Ratio
- STFS $108.79
- LPCN N/A
- Revenue Growth
- STFS 75.86
- LPCN N/A
- 52 Week Low
- STFS $0.80
- LPCN $2.68
- 52 Week High
- STFS $17.91
- LPCN $8.71
- Technical
- Relative Strength Index (RSI)
- STFS N/A
- LPCN 51.52
- Support Level
- STFS N/A
- LPCN $3.13
- Resistance Level
- STFS N/A
- LPCN $3.53
- Average True Range (ATR)
- STFS 0.00
- LPCN 0.24
- MACD
- STFS 0.00
- LPCN 0.01
- Stochastic Oscillator
- STFS 0.00
- LPCN 48.33
About STFS STAR FASHION CULTURE HOLDINGS LIMITED
Star Fashion Culture Holdings Ltd is a content marketing solutions services provider. The company offer services focusing on marketing campaign planning and execution, offline advertising services; and online precision marketing services. The services also include marketing campaign planning and execution, events including marathons, sports events, and music festivals.
About LPCN Lipocine Inc.
Lipocine Inc is a clinical-stage biopharmaceutical company, that is engaged in research and development for the delivery of drugs using its proprietary delivery technology. Its principal operation is to provide oral delivery solutions for existing drugs. Lipocine develops its drug candidates or it develops drug candidates on behalf of or in collaboration with corporate partners. The company's product TLANDO is an oral testosterone replacement therapy ("TRT"). It also has other products in the pipeline such as LPCN 1144, TLANDO, TLANDO XR, LPCN 1148, LPCN 1107, LPCN 1154, and LIP'RAL7 Technology. The Company has a single reportable segment, research, and development for the delivery of drugs using its proprietary delivery technology.